Jamie Smith
Media Relations
Email: jamie.smith@molnlycke.com
Mölnlycke Health Care accelerates U.S. growth journey with three wound care product launches
Peachtree Corners, GA. 7 July, 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, has launched three product innovations in the U.S. since the start of 2026. Designed to expand access to advanced wound care solutions and strengthen the company’s U.S. presence, the portfolio expansion also supports long-term value creation across key market segments.
Driven by the ambition to deliver customer-centric innovation, the launches reinforce Mölnlycke’s commitment to advancing standards in wound care and patient handling in the U.S.
Mölnlycke product launches since the start of 2026:
- Granudacyn® Wound Wash Solution
- Tortoise® Lite Turning and Positioning System
- Mepi® Press 2 & Mepi® Press Lite Compression System
In a healthcare environment facing increasing operational pressure and workforce constraints, Mölnlycke focuses on solutions that strengthen value-based care delivery across acute and out-of-hospital care settings. These innovations address key challenges for healthcare professionals, including better clinical and operational outcomes, safe patient handling and consistent wound management. Each of the new offerings plays a strategic role:
Granudacyn® Wound Wash Solution: A biocompatible, non-cytotoxic wound cleanser offers a gentle and effective way to cleanse both acute and chronic wounds, reducing discomfort and simplifying wound care. For clinicians and caregivers, this means safe wound preparation that fits seamlessly into existing protocols.
Tortoise® Lite Turning and Positioning System: A simplified, ergonomic system that supports safe and effective patient repositioning. Designed to remain under the patient throughout care, Tortoise® Lite aims to reduce caregiver strain and promote consistent pressure relieving practices.
Mepi® Press 2 & Mepi® Press 2 Lite Compression System: A multi-layer solution designed to deliver consistent compression therapy across a wide range of patient needs for venous disease and edema. Together with Mölnlycke advanced Mepilex® Up wound dressings and Granudacyn Wound Wash, Mepi Press 2 seamlessly integrates into care protocols, strengthening the end-to-end venous leg ulcer management for clinicians and improving clinical outcomes for patients.
“2026 marks an important year in our strategy to expand access to safe, intuitive and clinically reliable solutions,” said Craig Kennedy, Vice President Commercial Wound Care - Americas at Mölnlycke Health Care. “With these three major launches, we are reinforcing our mission to elevate standard of care and equip healthcare professionals with tools that make a meaningful impact in both patient outcomes and care delivery.”
Each product will be available through Mölnlycke Health Care U.S. and authorized distribution partners, https://www.molnlycke.com/en-us/
Note to Editors
Media background documents for each product:
Media backgrounder_Granudacyn US .pdf
Media backgrounder_Tortoise US.pdf
Media backgrounder_MepiPress US.pdf
For more information, please contact:
Latest news
-
Changes to Mölnlycke Health Care Board of Directors
Gothenburg, Sweden. 23 June 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, today announces changes to its Board of Directors. Christian Cederholm will leave his Board assignment, while Filippa Stenberg will take his place as member of the Board. Thomas Kidane will step in as deputy board member.
-
Mölnlycke Health Care strengthens global manufacturing footprint to power future growth in wound care
Gothenburg, Sweden. 8 June 2026. Mölnlycke Health Care (“Mölnlycke®”), a global leader in MedTech, today confirmed a combined investment of approximately EUR 40 million in Mikkeli, Finland, and Oldham, UK. The investments strengthen the company’s global wound care manufacturing network by increasing capacity, optimising process quality and enhancing supply chain resilience and sustainability.
-
Mölnlycke Health Care and Zhende Medical form pioneering joint venture to expand access to advanced wound care solutions in China
Gothenburg, Sweden, and Shanghai, China. 21 May 2026.
Mölnlycke Health Care (“Mölnlycke®”), a global leader in MedTech and advanced wound care solutions, and Zhende Medical, a leading supplier of medical care and protection in China, today announce the formation of a new joint venture company in China to accelerate growth in one of the world’s fastest-growing wound care markets. The joint venture, majority-owned by Mölnlycke, will integrate the two companies’ wound care portfolios and commercial capabilities to offer healthcare providers, patients and the public expanded access to advanced treatments, improved care delivery and better patient outcomes across China. -
Simple glove change could save the NHS £45 million over five years and improve caesarean safety
Gothenburg, Sweden. 27 April 2026. A new study1 published in the Journal of Hospital Infection shows that introducing a simple glove change during caesarean birth could deliver millions in cost savings for the National Health Service (NHS) in England.
-
Mölnlycke Health Care announces Andreas Johansson as Interim Chief Financial Officer
Gothenburg, Sweden. Wednesday 15 April 2026. Mölnlycke Health Care announces today the appointment of Andreas Johansson as Interim Chief Financial Officer (CFO), with immediate effect.
-
Mölnlycke Health Care annual report 2025 highlights sustainable growth and strategic transformation
Gothenburg, Sweden. 1 April 2026. Today, Mölnlycke Health Care has published its annual report 2025, including sustainability report, outlining the company’s continued focus on revolutionising care for people and planet.
-
Europe faces a growing chronic wound crisis – time to act is now
Gothenburg, Sweden. 31 March 2026. Mölnlycke®, a global leader in MedTech, today welcomes the publication of Shaping the future of wound care in Europe, the first joint industry white paper from the MedTech Europe Wound Care Sector Working Group. The wound paper highlights the growing burden of chronic wounds and urges EU policymakers to elevate wound care as a strategic health priority across the EU.
-
Mölnlycke Health Care AB: CEO, Zlatko Rihter, announces resignation, Guillaume Joucla appointed interim CEO
Tue, Mar 24, 2026 Today, it was announced that Zlatko Rihter, CEO of Mölnlycke Health Care, has informed the Board of Directors of his decision to resign. Following his decision, Guillaume Joucla, Chief Financial Officer, has been appointed interim CEO of Mölnlycke Health Care. Mölnlycke’s Board has initiated the recruitment process for a permanent CEO.
-
Mölnlycke joins National Climate Initiative within healthcare and life science
A broad public–private partnership is now being launched to accelerate the green transition within the Swedish healthcare and life science sector. The initiative aims, through collaboration, to reduce greenhouse gas emissions with the ambition of reaching net zero across the entire value chain by 2045.